Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Oncogene. 2012 Feb 23;31(8):1013-23. doi: 10.1038/onc.2011.299. Epub 2011 Jul 18.
Peroxisome proliferator-activated receptor γ (PPARγ) may serve as a useful target for drug development in non-diabetic diseases. However, some colorectal cancer cells are resistant to PPARγ agonists by mechanisms that are poorly understood. Here, we provide the first evidence that elevated PPARδ expression and/or activation of PPARδ antagonize the ability of PPARγ to induce colorectal carcinoma cell death. More importantly, the opposing effects of PPARδ and PPARγ in regulating programmed cell death are mediated by survivin and caspase-3. We found that activation of PPARγ results in decreased survivin expression and increased caspase-3 activity, whereas activation of PPARδ counteracts these effects. Our findings suggest that PPARδ and PPARγ coordinately regulate cancer cell fate by controlling the balance between the cell death and survival and demonstrate that inhibition of PPARδ can reprogram PPARγ ligand-resistant cells to respond to PPARγ agonists.
过氧化物酶体增殖物激活受体 γ(PPARγ)可能成为非糖尿病疾病药物开发的一个有用靶点。然而,一些结直肠癌细胞对 PPARγ 激动剂的耐药性机制尚不清楚。在这里,我们首次提供证据表明,升高的 PPARδ 表达和/或 PPARδ 的激活拮抗了 PPARγ 诱导结直肠癌细胞死亡的能力。更重要的是,PPARδ 和 PPARγ 调节程序性细胞死亡的拮抗作用是由 survivin 和 caspase-3 介导的。我们发现,激活 PPARγ 导致 survivin 表达减少和 caspase-3 活性增加,而激活 PPARδ 则拮抗这些作用。我们的研究结果表明,PPARδ 和 PPARγ 通过控制细胞死亡和存活之间的平衡来协调调节癌细胞命运,并证明抑制 PPARδ 可以使 PPARγ 配体耐药细胞重新编程以响应 PPARγ 激动剂。